Section snippets

Cabozantinib for advanced neuroendocrine tumours

Cabozantinib shows promise for patients with neuroendocrine tumours, according to the CABINET phase 3 trial. Jennifer A Chan and colleagues randomly assigned patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumours to receive either cabozantinib 60 mg or placebo daily. Among patients with pancreatic neuroendocrine tumours, a significant improvement in progression-free survival was observed in the cabozantinib group compared with the placebo

Preoperative chemoradiotherapy for gastric cancer

Preoperative chemoradiotherapy did not improve outcomes for patients with resectable gastric cancer in the TOPGEAR phase 3 trial. Trevor Leong and colleagues randomly assigned patients with resectable adenocarcinoma of the stomach or gastro-oesophageal junction to receive either preoperative chemoradiotherapy plus perioperative chemotherapy (n=286) or perioperative chemotherapy alone (standard of care; n=288). 36 (17%) of 214 patients in the preoperative chemoradiotherapy group had a

Peg-interferon after bepirovirsen for chronic hepatitis B

Sequential therapy with pegylated interferon-alfa-2b after bepirovirsen might reduce relapse rates seen in earlier trials of bepirovirsen alone in patients with chronic hepatitis B, according to the B-Together trial. Maria Buti and colleagues randomly assigned patients on stable nucleoside or nucleotide analogue therapy to receive bepirovirsen 300 mg once weekly for 24 weeks (n=55) or 12 weeks (n=53), followed by pegylated interferon-alfa-2b 180 μg once weekly for up to 24 weeks, with up to 36

Terlipressin in decompensated cirrhosis

Long-term terlipressin therapy might improve cardiac reserve in patients with decompensated cirrhosis, according to new research. Ryma Terbah and colleagues enrolled 22 patients to receive home continuous terlipressin infusion for 12 weeks. The increase in cardiac output in response to low-dose dobutamine was significantly higher following terlipressin (4·0 L/min [57·8% increase]) as compared with baseline (1·8 L/min [21·3% increase]; p=0·0001). The proportion of patients with impaired cardiac

GALAD score for hepatocellular carcinoma surveillance

The GALAD score might be better than α-fetoprotein as a biomarker for the detection of hepatocellular carcinoma, according to a phase 3 biomarker validation study. Tracey L Marsh and colleagues enrolled 1588 patients with cirrhosis and followed them up for a median of 2·2 years. Patients underwent surveillance for hepatocellular carcinoma every 6 months and diagnoses were confirmed according to AASLD guidelines. The performance of GALAD versus α-fetoprotein was retrospectively evaluated within

中文翻译：

---

 研究简介

 部分片段

卡博替尼用于晚期神经内分泌肿瘤

根据 CABINET 3 期试验，卡博替尼对神经内分泌肿瘤患者显示出前景。Jennifer A Chan 及其同事将既往接受过治疗的进行性晚期胰腺外或胰腺神经内分泌肿瘤患者随机分配至每天接受卡博替尼 60 mg 或安慰剂治疗。在胰腺神经内分泌肿瘤患者中，与安慰剂组相比，卡博替尼组观察到无进展生存期显著改善

胃癌的术前放化疗

在 TOPGEAR 3 期试验中，术前放化疗并未改善可切除胃癌患者的预后。Trevor Leong 及其同事将可切除的胃或胃食管交界处腺癌患者随机分配接受术前放化疗加围手术期化疗 （n=286） 或单独围手术期化疗 （标准护理;n=288）。术前放化疗组 214 例患者中有 36 例 （17%）

贝吡罗韦森后 PEG-干扰素治疗慢性乙型肝炎

根据 B-Together 试验，在贝吡罗韦森后使用聚乙二醇干扰素-α-2b 序贯治疗可能会降低早期单独使用贝吡罗韦森治疗慢性乙型肝炎患者的复发率。Maria Buti 及其同事将接受稳定核苷或核苷酸类似物治疗的患者随机分配接受贝吡罗维森 300 毫克，每周一次，持续 24 周 （n=55） 或 12 周 （n=53），然后聚乙二醇干扰素-α-2b 180 μg 每周一次，持续长达 24 周，最多 36 周

特利加压素治疗失代偿期肝硬化

根据新的研究，长期特利加压素治疗可能会改善失代偿性肝硬化患者的心脏储备。Ryma Terbah 及其同事招募了 22 名患者接受家庭连续特利加压素输注 12 周。与基线 （1·8 L/min [21·3% 增加];p=0·0001） 相比，特利加压素 （4·0 L/min [增加 57·8%） 相比，低剂量多巴酚丁胺后心输出量的增加显著增加。心脏功能受损患者比例

肝细胞癌监测的 GALAD 评分

根据一项 3 期生物标志物验证研究，GALAD 评分作为检测肝细胞癌的生物标志物可能优于α胎蛋白。Tracey L Marsh 及其同事招募了 1588 名肝硬化患者，并对他们进行了中位随访 2·2 年。患者每 6 个月接受一次肝细胞癌监测，并根据 AASLD 指南确认诊断。回顾性评价 GALAD 与 α-fetoprotein 的性能